This week Shanti is joined by Dr. James Kupiec, Chief Medical Officer at ProMIS Neurosciences. Shanti and Dr. Kupiec do a deep dive on Biomarkers and discuss recent research coming out of AAIC.

Elliot is back to discuss the TDP43 protein, which has been implicated in the development of a recently discovered form of dementia as well as ALS. Shanti and Elliot talk about why TDP43 is important, and the efforts to neutralize the misfolded protein in the brain before it can destroy brain cells.

This week Shanti and Dr. Johanne Kaplan recap AAIC 2019 and discuss the exciting data that came out of the conference. For more information check out https://promisneurosciences.com/

This week Shanti and Johanne preview AAIC and discuss what the hot topics at the conference are expected to be.

This week Shanti discusses some of the most exciting news coming out of the recent 2019 Keystone Symposia with Dr. Johanne Kaplan.

Shanti is joined by Dr. Johanne Kaplan, the Chief Development Officer at ProMIS Neurosciences. The two discuss Dr. Kaplan's career, and the current challenges researchers must tackle as they continue their search for a way to stop Alzheimer's disease. The two also discuss Dr. Kaplan's recent paper on the importance of selectivity in drug development for Alzheimer's.

Toxic tau and amyloid-beta are the two most validated drug targets for an Alzheimers disease therapy. Elliot and Shanti discuss tau, its role as a root cause of Alzheimer's disease and its involvement in 80 other diseases known as tauopathies.

Dr. Goldstein and Shanti breakdown the news of the week. This week they discuss two major late-stage failures for promising Alzheimer's drugs, a new syndrome that is similar to Alzheimer's, and some important biomarker developments.

This is part two of our exploration of biomarkers. Elliot and Shanti discuss how biomarkers work and how they will play a critical role in the future of drug development for the various brain-wasting diseases.

Dr. Goldstein and Shanti discuss why biomarkers are becoming increasingly important in the medical community. They also discuss how biomarkers are uniquely important in the quest for a cure for Alzheimer's.